GGrantIndex
← Leaderboards

Central Texas Veterans Research Foundation

Temple, TX

Compare ↔
$4,805,572
Total funding
5
Grants

Funding over time

peak $985.1K · FY2008–23
$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

DOD$2,521,105 · 3
AHRQ$2,284,467 · 2

By mechanism

—$2,521,105 · 3
R01$2,199,677 · 1
R03$84,790 · 1

Investigators at Central Texas Veterans Research Foundation

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

1Chetan Jinadatha$2,199,6771 gr2Piyali Chatterjee$84,7901 gr

All-Time

Most funded here, all years

1Chetan Jinadatha$2,199,6771 gr2Piyali Chatterjee$84,7901 gr

Largest grants

INFLAMMATION MODULATORY PROTEIN TSG-6 FOR CHEMICAL INJURIES TO THE CORNEA$985,149
· FY2014 · Department of Defense
A PILOT RCT ON THE EFFECT OF RESVERATROL ON MOOD, MEMORY DEFICITS, HIPPOCAMPAL INFLAMMATION, AND NEUROGENESIS IN VETERANS WITH GULF WAR ILLNESS (GWI)$787,197
· FY2017 · Defense Health Agency
PREDICTORS OF TREATMENT RESPONSE TO FLUOXETINE IN PTSD FOLLOWING A RECENT HISTORY OF WAR ZONE STRESS EXPOSURE$748,759
· FY2008 · Department of Defense
A Trial to Explore the Benefits of Antimicrobial Self-Sanitizing Surfaces on Bio-Burden Levels and Healthcare-Acquired Infections.$484,985
R01 · FY2019 · HS
A Trial to Explore the Benefits of Antimicrobial Self-Sanitizing Surfaces on Bio-Burden Levels and Healthcare-Acquired Infections.$480,279
R01 · FY2020 · HS
A Trial to Explore the Benefits of Antimicrobial Self-Sanitizing Surfaces on Bio-Burden Levels and Healthcare-Acquired Infections.$453,389
R01 · FY2021 · HS
A Trial to Explore the Benefits of Antimicrobial Self-Sanitizing Surfaces on Bio-Burden Levels and Healthcare-Acquired Infections.$442,710
R01 · FY2022 · HS
A Trial to Explore the Benefits of Antimicrobial Self-Sanitizing Surfaces on Bio-Burden Levels and Healthcare-Acquired Infections.$338,314
R01 · FY2023 · HS
Understanding mechanisms and implications of Acinetobacter carbapenem resistance via whole genome sequencing and associated patient outcomes$42,395
R03 · FY2020 · HS
Understanding mechanisms and implications of Acinetobacter carbapenem resistance via whole genome sequencing and associated patient outcomes$42,395
R03 · FY2021 · HS